Lexaria Bioscience Announces the Issuance of Options and Warrants
Kelowna, British Columbia – May 23, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that on May 22, 2019…
Lexaria Bioscience and Nuka Enterprises’ 1906 Expand Cannabis Product Relationship
1906 fast-acting edibles products, powered by Lexaria’s DehydraTECH technology, will expand across the US in 2019 and 2020 Kelowna, British Columbia – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), an innovator…
Lexaria’s DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
The DehydraTECH formulation delivered measurable quantities of cannabidiol (“CBD”) into blood in as little as 2 minutes; Lexaria’s technology delivered more CBD to bloodstream in 15 minutes than conventional medium…
Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company
Kelowna, British Columbia – May 7, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a…
Lexaria Bioscience Expands Advisory Board
Kelowna, British Columbia – April 25, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce new appointments…
Lexaria Bioscience Announces Beverage License Agreement with California-Based Cannabis Company
Kelowna, British Columbia – April 24, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a…
Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services
Kelowna, BC – April 15, 2019 – Lexaria Bioscience Corp. (CNSX: LXX) (OTCQB: LXRP) (“Lexaria” or the “Company”) announces it has retained Oak Hill Financial Inc. (“Oak Hill”) to provide…
Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options
Kelowna, British Columbia – April 9, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has successfully negotiated…
Lexaria Bioscience Begins Largest Cannabinoid R&D Program in its History
Kelowna, British Columbia – March 20, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that work has commenced on…
Lexaria Bioscience comments on FDA Statement on Novel Nicotine Replacement Therapies
Kelowna, British Columbia – February 26, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, comments on the February 21, 2019…